

Plague Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P4BD4AAC85DCEN.html>

Date: March 2022

Pages: 46

Price: US\$ 2,000.00 (Single User License)

ID: P4BD4AAC85DCEN

Abstracts

Plague Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plague - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium *Yersinia pestis*. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plague - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical, Discovery and Unknown stages are 5, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Plague - Overview
- Plague - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Plague - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Plague - Companies Involved in Therapeutics Development
 - Enesi Pharma Ltd
 - FasCure Therapeutics LLC
 - Greffex Inc
 - iBio Inc
 - Mapp Biopharmaceutical Inc
 - Norwell Inc
 - Opal Biosciences Ltd
 - Prokarium Ltd
- Plague - Drug Profiles
 - (anthrax + plague) (multivalent) vaccine - Drug Profile
 - Product Description
 - Mechanism Of Action
 - anthrax + plague vaccine - Drug Profile
 - Product Description
 - Mechanism Of Action
 - BDM-I - Drug Profile
 - Product Description
 - Mechanism Of Action
 - GrePla - Drug Profile
 - Product Description
 - Mechanism Of Action
 - History of Events

ISAS-02 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibodies for Plague - Drug Profile
Product Description
Mechanism Of Action
plague (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
plague vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
pneumonic plague vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Plague - Drug Profile
Product Description
Mechanism Of Action

VypVaxDuo - Drug Profile

Product Description

Mechanism Of Action

Plague - Dormant Projects

Plague - Discontinued Products

Plague - Product Development Milestones

Featured News & Press Releases

Oct 31, 2019: Clinical development of a new vaccine for rapid response against Plague:
GMP

Oct 31, 2016: Rapid, simple manufacture and clinical evaluation of an oral plague
vaccine

Sep 30, 2016: Self-administered vaccines directed against Plague and MERS

Feb 14, 2013: BioDiem Extends Cooperative Agreement With USAMRIID

May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against
Plague

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Plague, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Plague - Pipeline by Enesi Pharma Ltd, 2022
Plague - Pipeline by FasCure Therapeutics LLC, 2022
Plague - Pipeline by Greffex Inc, 2022
Plague - Pipeline by iBio Inc, 2022
Plague - Pipeline by Mapp Biopharmaceutical Inc, 2022
Plague - Pipeline by Norwell Inc, 2022
Plague - Pipeline by Opal Biosciences Ltd, 2022
Plague - Pipeline by Prokarium Ltd, 2022
Plague - Dormant Projects, 2022
Plague - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Plague, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Plague Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P4BD4AAC85DCEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P4BD4AAC85DCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

